Olivier Colliot
Olivier Colliot - Research Director at CNRS - ARAMIS Lab at the Paris Brain Institute (CNRS/Inria/Inserm/Sorbonne Universite)
3
Documents
Identifiants chercheurs
- olivier-colliot
- ResearcherId : B-2092-2012
- 0000-0002-9836-654X
- IdRef : 085263893
- Arxiv : colliot_o_1
- ResearcherId : http://www.researcherid.com/rid/B-2092-2012
Présentation
Research Director at [CNRS](http://www.cnrs.fr/)
Head of the [ARAMIS Lab](http://www.aramislab.fr/), a joint team between [CNRS](http://www.cnrs.fr/), [Inria](http://www.inria.fr/), [Inserm](http://www.inserm.fr/) and [University Pierre and Marie Curie](http://www.upmc.fr/) at the [Paris Brain Institute (ICM)](http://www.icm-institute.org/), in co-direction with Stanley Durrleman.
Homepage: <https://www.aramislab.fr/perso/colliot/>
Email: olivier.colliot@cnrs.fr
Research Director at [CNRS](http://www.cnrs.fr/)
Head of the [ARAMIS Lab](http://www.aramislab.fr/), a joint team between [CNRS](http://www.cnrs.fr/), [Inria](http://www.inria.fr/), [Inserm](http://www.inserm.fr/) and [University Pierre and Marie Curie](http://www.upmc.fr/) at the [Paris Brain Institute (ICM)](http://www.icm-institute.org/), in co-direction with Stanley Durrleman.
Homepage: <https://www.aramislab.fr/perso/colliot/>
Email: olivier.colliot@cnrs.fr
Domaines de recherche
Intelligence artificielle [cs.AI]
Imagerie médicale
Apprentissage [cs.LG]
Traitement des images [eess.IV]
Publications
- 3
- 3
- 3
- 3
- 3
- 3
- 2
- 1
- 2
- 2
- 3
- 1
- 1
|
Reduction of recruitment costs in preclinical AD trials. Validation of automatic pre-screening algorithm for brain amyloidosisStatistical Methods in Medical Research, 2019, pp.096228021882303. ⟨10.1177/0962280218823036⟩
Article dans une revue
hal-01964942v2
|
|
Prediction of amyloidosis from neuropsychological and MRI data for cost effective inclusion of pre-symptomatic subjects in clinical trialsMultimodal Learning for Clinical Decision Support, Sep 2017, Quebec City, Canada
Communication dans un congrès
hal-01578422v1
|
|
Selection of amyloid positive pre-symptomatic subjects using automatic analysis of neuropsychological and MRI data for cost effective inclusion procedures in clinical trialsClinical Trials for Alzheimer's Disease, Nov 2017, Boston, United States. pp.295
Communication dans un congrès
hal-02098434v2
|